Skip to main content


Welcome to contact Moberg Pharma for collaboration/licensing in the following projects:

  • MOB-015 - Onychomycosis (nail fungus) – Registration preperations are ongoing
    MOB-015 is a new topical treatment for onychomycosis (nail fungus) with antifungal, keratolytic, and emollient properties. The company’s patented formulation technology facilitates delivery of high concentrations of a proven antifungal substance (terbinafine) into and through the nail. Since MOB-015 is applied locally, adverse events associated with oral treatments can be avoided. The company estimates the sales potential of MOB-015 to USD 250–500 million annually.

    Several attractive licensing agreements for MOB-015 are already in place in Europe (Bayer), South Korea (Dongkoo), Scandinavia (Allderma), Canada (Cipher) and Israel (Padagis) and we look forward to entering into more exciting partnerships in the future.